-
If you purchased shares of NxStage Medical, Inc. (NASDAQ:NXTM) and currently hold any of those NASDAQ:NXTM shares, you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
August 14, 2017 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of NxStage Medical, Inc. (NASDAQ:NXTM), was announced concerning whether the takeover of NxStage Medical, Inc. by Fresenius Medical Care for $30.00 per share is unfair to NASDAQ:NXTM stockholders.
The investigation by a law firm concerns whether certain officers and directors of NxStage Medical, Inc. breached their fiduciary duties owed to NASDAQ:NXTM investors in connection with the proposed acquisition.
On August 7, 2017, Fresenius Medical Care has signed an agreement to acquire NxStage Medical, Inc. (NASDAQ:NXTM). Under the terms of the proposed transaction, Fresenius Medical Care would acquire NxStage in a transaction valued at approximately $2 billion or $30.00 in cash per share.
However, given that at least one analyst set a price target NASDAQ:NXTM stock at $33.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:NXTM stockholders. More specifically, the investigation concerns whether the NxStage Medical Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
